1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,253 | 0,289 | 17:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:38 | Invitation to the Presentation of Cantargia's H1 2025 Report | 176 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August... ► Artikel lesen | |
| 17.07. | Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer | 308 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated... ► Artikel lesen | |
| 16.07. | Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer | 266 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival... ► Artikel lesen | |
| 15.07. | Otsuka to acquire Cantargia's CAN10 for autoimmune diseases | 3 | Pharmaceutical Technology | ||
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 15.07. | Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical | 337 | ACCESS Newswire | Cantargia receives an upfront cash payment of USD 33 million.Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments... ► Artikel lesen | |
| 17.06. | Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans | 303 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million... ► Artikel lesen | |
| 17.06. | Cantargia Q1 2025 slides: CAN10 advances amid funding challenges | 3 | Investing.com | ||
| 11.06. | Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation | 751 | ACCESS Newswire | Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development... ► Artikel lesen | |
| 19.05. | Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation | 233 | ACCESS Newswire | IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,... ► Artikel lesen | |
| 15.05. | Bulletin from the Annual General Meeting in Cantargia AB | 293 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge... ► Artikel lesen | |
| 13.05. | Cantargia Publishes Interim Report for the First Quarter of 2025 | 441 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first... ► Artikel lesen | |
| 12.05. | Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 | 258 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model... ► Artikel lesen | |
| 06.05. | Cantargia's Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors | 288 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications... ► Artikel lesen | |
| 29.04. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2025 | 239 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025... ► Artikel lesen | |
| 29.04. | Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10 | 229 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets... ► Artikel lesen | |
| 28.04. | Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression | 130 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 28, 2025 / Cantargia (STO:CANTA)Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy... ► Artikel lesen | |
| 25.04. | Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate at a Major Cancer Conference | 440 | ACCESS Newswire | Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment... ► Artikel lesen | |
| 25.04. | Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy at AACR | 378 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention... ► Artikel lesen | |
| 11.04. | Cantargia Publishes Annual Report 2024 | 344 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The... ► Artikel lesen | |
| 11.04. | Notice of Annual General Meeting in Cantargia AB | 290 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon... ► Artikel lesen |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,45 | +0,32 % | Novo Nordisk Aktie: Heftig! - Allianz, BioNTech, Heidelberger, Infineon und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 6,582 | +0,12 % | Evotec Aktie: Die Bullen in der Falle? | Die Evotec Aktie steht erneut im Zentrum charttechnischer Spannung. Nachdem der Kurs der Biotech-Aktie Ende Juli kurzzeitig über die 200-Tage-Linie ausgebrochen war, entpuppte sich dieser Anstieg schnell... ► Artikel lesen | |
| QIAGEN | 41,895 | +1,90 % | Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben | DJ Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben
DOW JONES--Qiagen hat mit den Ergebnissen für das zweite Quartal die Erwartungen übertroffen und den Ausblick für das... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 483,50 | +2,72 % | Truist Securities lowers Regeneron Pharma stock price target on Eylea concerns | ||
| BRAIN BIOTECH | 1,970 | -1,50 % | EQS-News: BRAIN Biotech AG: Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Personalie
Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG
23.07.2025 / 08:30 CET/CEST
Für den... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,900 | +1,81 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,930 | +3,21 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Production of Fava Protein and Officially Launches FavaPro 90%+ Pure Plant Protein | Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CSL | 146,82 | +0,41 % | What to do with your CBA, BHP, and CSL shares now: experts | ||
| MANNKIND | 2,925 | -0,88 % | MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement | Strengthens MannKind's capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK,... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 2,410 | -0,82 % | Oxford Nanopore Technologies: ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology | New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers
ViruSure, a global leader in pathogen safety testing for biopharmaceuticals... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,660 | -1,48 % | Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data | ||
| ADAPTIMMUNE THERAPEUTICS | 0,067 | -14,10 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
| CODEXIS | 2,448 | +1,58 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| TELO GENOMICS | 0,014 | 0,00 % | Telo Genomics Corp.: Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference | Toronto, Ontario--(Newsfile Corp. - August 5, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,02 % bei einem Aktienkurs von 0,243 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.